Pfizer Financial Statements From 2010 to 2025

PFE Stock  USD 26.15  0.10  0.38%   
Pfizer financial statements provide useful quarterly and yearly information to potential Pfizer Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pfizer financial statements helps investors assess Pfizer's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pfizer's valuation are summarized below:
Gross Profit
47.2 B
Profit Margin
0.1262
Market Capitalization
145.9 B
Enterprise Value Revenue
2.9711
Revenue
63.6 B
There are over one hundred nineteen available trending fundamental ratios for Pfizer Inc, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Pfizer's recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 126.1 B. The current year's Enterprise Value is expected to grow to about 87.3 B

Pfizer Total Revenue

40.24 Billion

Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.4 B, Interest Expense of 3.2 B or Total Revenue of 40.2 B, as well as many indicators such as Price To Sales Ratio of 4.57, Dividend Yield of 0.0665 or PTB Ratio of 1.62. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
Check out the analysis of Pfizer Correlation against competitors.

Pfizer Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets107.7 B213.4 B164.9 B
Slightly volatile
Short and Long Term Debt Total66.8 B63.6 B43 B
Slightly volatile
Other Current Liabilities30.4 B28.9 B16.6 B
Slightly volatile
Total Current Liabilities21.5 B43 B30.4 B
Slightly volatile
Total Stockholder Equity48.2 B88.2 B68.6 B
Slightly volatile
Property Plant And Equipment Net11.5 B18.4 B13.7 B
Slightly volatile
Net Debt65.7 B62.6 B40.2 B
Slightly volatile
Retained Earnings122.6 B116.7 B84 B
Slightly volatile
CashBB2.5 B
Slightly volatile
Non Current Assets Total171.2 B163 B126.2 B
Slightly volatile
Non Currrent Assets Other5.5 B9.8 B5.3 B
Slightly volatile
Cash And Short Term Investments15.1 B20.5 B20.8 B
Pretty Stable
Net Receivables8.8 B14.8 B12.3 B
Very volatile
Common Stock Shares Outstanding5.8 B5.7 B4.8 B
Pretty Stable
Liabilities And Stockholders Equity107.7 B213.4 B164.9 B
Slightly volatile
Non Current Liabilities Total86 B81.9 B68.6 B
Slightly volatile
Inventory11.4 B10.9 B7.7 B
Slightly volatile
Other Current Assets2.5 B4.3 B2.9 B
Slightly volatile
Total Liabilities131.1 B124.9 B100.5 B
Slightly volatile
Property Plant And Equipment Gross36.6 B34.9 B20.1 B
Slightly volatile
Total Current Assets32.8 B50.4 B44.6 B
Very volatile
Short Term Debt5.7 B6.9 B6.8 B
Pretty Stable
Intangible Assets58.2 B55.4 B41.4 B
Slightly volatile
Property Plant Equipment11.3 B21.8 B13.9 B
Slightly volatile
Accounts PayableB5.6 B4.3 B
Slightly volatile
Common Stock Total Equity474 M549.7 M453.4 M
Slightly volatile
Short Term Investments20.1 B19.4 B19 B
Very volatile
Capital Stock476.1 M480 M449.1 M
Slightly volatile
Common Stock476.1 M480 M449.1 M
Slightly volatile
Other Liabilities22.1 B26.9 B26.2 B
Pretty Stable
Other AssetsB7.7 BB
Slightly volatile
Long Term Debt59.5 B56.7 B35.9 B
Slightly volatile
Good Will42.1 B68.5 B48.5 B
Slightly volatile
Current Deferred Revenue1.4 B1.5 B3.9 B
Slightly volatile
Preferred Stock Total Equity14.5 M15.3 M35.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity265.1 M246.6 M314.4 M
Slightly volatile
Retained Earnings Total Equity87 B136.1 B85.4 B
Slightly volatile
Long Term Debt Total39.6 B70.8 B38.2 B
Slightly volatile
Capital Surpluse90 B106.5 B84.5 B
Slightly volatile
Deferred Long Term Liabilities547.2 M576 M11.7 B
Slightly volatile
Long Term Investments2.1 B2.2 B12.5 B
Pretty Stable
Non Current Liabilities Other16.8 B14.2 B20.8 B
Slightly volatile
Short and Long Term Debt7.8 B6.9 B6.1 B
Slightly volatile
Cash And Equivalents1.8 B3.3 B2.1 B
Slightly volatile
Net Invested Capital136.4 B151.9 B120.3 B
Slightly volatile

Pfizer Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.4 BB3.7 B
Slightly volatile
Total Revenue40.2 B63.6 B54.8 B
Slightly volatile
Gross Profit31 B47.2 B40.4 B
Pretty Stable
Other Operating Expenses29.3 B42.1 B39.9 B
Slightly volatile
Operating Income11.1 B14.9 B15.2 B
Pretty Stable
EBIT12.7 B11.1 B16.8 B
Very volatile
EBITDA15.5 B18.1 B20.2 B
Pretty Stable
Cost Of Revenue9.3 B16.4 B14.4 B
Slightly volatile
Total Operating Expenses20 B25.6 B25.5 B
Pretty Stable
Income Before Tax8.9 BB12.3 B
Pretty Stable
Net Income8.4 BB12.4 B
Pretty Stable
Selling General Administrative13 B14.7 B11.8 B
Very volatile
Research Development8.4 B10.8 B8.6 B
Slightly volatile
Net Income Applicable To Common Shares37.9 B36.1 B18.2 B
Slightly volatile
Net Income From Continuing Ops13.1 B8.1 B12.2 B
Pretty Stable
Non Recurring1.3 B2.1 B1.6 B
Slightly volatile
Selling And Marketing Expenses2.2 B3.3 B2.8 B
Pretty Stable
Interest Income891.9 M545 M1.1 B
Slightly volatile
Reconciled Depreciation4.4 BB5.8 B
Slightly volatile

Pfizer Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow10.6 B9.8 B14 B
Very volatile
Begin Period Cash Flow2.1 B2.9 B2.5 B
Pretty Stable
Depreciation4.2 BB5.7 B
Very volatile
Dividends Paid5.3 B9.5 B7.2 B
Slightly volatile
Capital Expenditures1.9 B2.9 B2.2 B
Slightly volatile
Total Cash From Operating Activities12.5 B12.7 B16.1 B
Pretty Stable
Net Income9.3 B8.1 B12.5 B
Pretty Stable
End Period Cash Flow2.1 B1.1 B2.6 B
Slightly volatile
Stock Based Compensation920.9 M877 M692.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.572.36173.5258
Slightly volatile
Dividend Yield0.06650.06330.0403
Slightly volatile
PTB Ratio1.621.70362.7437
Very volatile
Days Sales Outstanding80.1584.769163.3826
Very volatile
Book Value Per Share16.4115.624511.8504
Slightly volatile
Free Cash Flow Yield0.04470.06550.0675
Pretty Stable
Operating Cash Flow Per Share1.452.252.6155
Slightly volatile
Stock Based Compensation To Revenue0.00940.01380.0119
Slightly volatile
Capex To Depreciation0.390.41480.5009
Pretty Stable
PB Ratio1.621.70362.7437
Very volatile
EV To Sales3.633.34564.0998
Pretty Stable
Free Cash Flow Per Share1.211.73642.2559
Pretty Stable
ROIC0.140.08450.1065
Pretty Stable
Inventory Turnover1.311.51321.87
Slightly volatile
Net Income Per Share0.991.41792.0197
Pretty Stable
Days Of Inventory On Hand270241220
Very volatile
Payables Turnover2.632.9153.3614
Very volatile
Sales General And Administrative To Revenue0.330.220.2368
Slightly volatile
Research And Ddevelopement To Revenue0.130.17010.1551
Pretty Stable
Capex To Revenue0.06030.04570.0434
Slightly volatile
Cash Per Share3.83.61533.4284
Very volatile
POCF Ratio21.8711.791113.3905
Slightly volatile
Interest Coverage4.594.832712.3536
Slightly volatile
Payout Ratio1.241.18440.9302
Slightly volatile
Capex To Operating Cash Flow0.310.22830.1947
Very volatile
PFCF Ratio14.5115.278718.0238
Pretty Stable
Days Payables Outstanding138125118
Pretty Stable
Income Quality1.181.58291.5765
Pretty Stable
ROE0.08650.09110.1751
Pretty Stable
EV To Operating Cash Flow23.8416.703716.0208
Slightly volatile
PE Ratio27.918.710721.6137
Slightly volatile
Return On Tangible Assets0.110.08980.154
Very volatile
EV To Free Cash Flow20.5621.644321.8429
Very volatile
Earnings Yield0.0440.05340.0624
Pretty Stable
Intangibles To Total Assets0.610.58080.5016
Slightly volatile
Net Debt To EBITDA3.633.45372.3049
Slightly volatile
Current Ratio1.731.17131.6152
Slightly volatile
Receivables Turnover4.214.30585.952
Pretty Stable
Graham Number23.422.289222.3177
Slightly volatile
Shareholders Equity Per Share16.3515.572611.8023
Slightly volatile
Debt To Equity0.760.72160.5757
Slightly volatile
Capex Per Share0.540.51360.3783
Slightly volatile
Revenue Per Share11.811.23369.3797
Slightly volatile
Interest Debt Per Share12.3711.78327.3438
Slightly volatile
Debt To Assets0.160.29830.228
Slightly volatile
Enterprise Value Over EBITDA15.5511.743412.9968
Slightly volatile
Short Term Coverage Ratios1.921.83473.4925
Pretty Stable
Price Earnings Ratio27.918.710721.6137
Slightly volatile
Operating Cycle351326283
Very volatile
Price Book Value Ratio1.621.70362.7437
Very volatile
Days Of Payables Outstanding138125118
Pretty Stable
Dividend Payout Ratio1.241.18440.9302
Slightly volatile
Price To Operating Cash Flows Ratio21.8711.791113.3905
Slightly volatile
Price To Free Cash Flows Ratio14.5115.278718.0238
Pretty Stable
Pretax Profit Margin0.170.12610.215
Pretty Stable
Ebt Per Ebit0.910.53710.7925
Pretty Stable
Operating Profit Margin0.210.23480.2631
Pretty Stable
Company Equity Multiplier1.712.41942.3312
Very volatile
Long Term Debt To Capitalization0.410.39130.3176
Slightly volatile
Total Debt To Capitalization0.240.41920.3456
Slightly volatile
Return On Capital Employed0.08330.08770.1198
Pretty Stable
Debt Equity Ratio0.760.72160.5757
Slightly volatile
Ebit Per Revenue0.210.23480.2631
Pretty Stable
Quick Ratio1.020.91891.3041
Slightly volatile
Dividend Paid And Capex Coverage Ratio1.261.0261.6943
Slightly volatile
Net Income Per E B T0.721.0011.031
Pretty Stable
Cash Ratio0.0230.02430.1075
Slightly volatile
Cash Conversion Cycle226201171
Slightly volatile
Operating Cash Flow Sales Ratio0.20.20030.2765
Pretty Stable
Days Of Inventory Outstanding270241220
Very volatile
Days Of Sales Outstanding80.1584.769163.3826
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.580.77170.7984
Pretty Stable
Cash Flow Coverage Ratios0.190.20020.4172
Pretty Stable
Price To Book Ratio1.621.70362.7437
Very volatile
Fixed Asset Turnover2.73.45933.8816
Very volatile
Capital Expenditure Coverage Ratio4.834.38097.7548
Slightly volatile
Price Cash Flow Ratio21.8711.791113.3905
Slightly volatile
Enterprise Value Multiple15.5511.743412.9968
Slightly volatile
Debt Ratio0.160.29830.228
Slightly volatile
Cash Flow To Debt Ratio0.190.20020.4172
Pretty Stable
Price Sales Ratio4.572.36173.5258
Slightly volatile
Return On Assets0.03580.03760.0767
Pretty Stable
Asset Turnover0.590.29820.381
Pretty Stable
Net Profit Margin0.150.12620.2138
Pretty Stable
Gross Profit Margin0.620.74190.7329
Slightly volatile
Price Fair Value1.621.70362.7437
Very volatile
Return On Equity0.08650.09110.1751
Pretty Stable

Pfizer Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap126.1 B120.1 B124.4 B
Slightly volatile
Enterprise Value87.3 B83.2 B86.3 B
Slightly volatile

Pfizer Fundamental Market Drivers

Forward Price Earnings8.658
Cash And Short Term Investments20.5 B

Pfizer Upcoming Events

7th of May 2024
Upcoming Quarterly Report
View
6th of August 2024
Next Financial Report
View
31st of March 2024
Next Fiscal Quarter End
View
4th of February 2025
Next Fiscal Year End
View
31st of December 2023
Last Quarter Report
View
31st of December 2023
Last Financial Announcement
View

About Pfizer Financial Statements

Pfizer stakeholders use historical fundamental indicators, such as Pfizer's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 B1.4 B
Total Revenue63.6 B40.2 B
Cost Of Revenue16.4 B9.3 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.22  0.33 
Research And Ddevelopement To Revenue 0.17  0.13 
Capex To Revenue 0.05  0.06 
Revenue Per Share 11.23  11.80 
Ebit Per Revenue 0.23  0.21 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.98)
Dividend Share
1.68
Earnings Share
1.41
Revenue Per Share
11.234
Quarterly Revenue Growth
0.219
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.